NASDAQ:GNRX VanEck Vectors Generic Drugs ETF (GNRX) Price, Holdings, & News → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free GNRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$22.42▼$22.4250-Day Range$22.42▼$22.4252-Week Range$20.17▼$26.19Volume4 shsAverage Volume1,310 shsMarket Capitalization$3.36 millionAssets Under Management$3.36 millionDividend Yield0.04%Net Expense Ratio0.57% Stock AnalysisStock Analysis Get VanEck Vectors Generic Drugs ETF alerts: Email Address About VanEck Vectors Generic Drugs ETFRead More Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. GNRX ETF News HeadlinesDecember 4, 2023 | msn.comVanEck Vectors Preferred Securities Ex Financials ETF declares monthly distribution of $0.1422November 10, 2023 | investing.comGDIG ETF Stock Price HistoryApril 18, 2023 | finance.yahoo.comVanEck Announces Changes to ETF Product LineMarch 3, 2023 | investing.comVanEck AEX UCITS ETF (TDT)January 22, 2023 | seekingalpha.comGDXJ VanEck Vectors Junior Gold Miners ETFJanuary 9, 2023 | thestreet.comGeneric Drug ETF Can Dodge Biotech SmackdownsJanuary 18, 2022 | thestreet.comGeneric Drug ETF Offering Portfolio CureSee More Headlines Receive GNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VanEck Vectors Generic Drugs ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerVan Eck Fund NameVanEck Vectors Generic Drugs ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:GNRX Inception Date1/12/2016 Fund ManagerHao-Hung (Peter) Liao, Guo Hua (Jason) Jin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkIndxx Global Generics & New Pharma Index CategorySector FocusHealth Care Development LevelBlended Development RegionGlobal Number of Holdings0 Fund Statistics Assets Under Management$3.36 million Average Daily Volume$591.00 Discount/Premium-0.42% Administrator, Advisor and Custodian AdministratorVan Eck Associates Corporation AdvisorVan Eck Associates Corporation CustodianThe Bank of New York Mellon Corporation DistributorVan Eck Securities Corporation Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCantor Fitzgerald Miscellaneous Outstanding Shares150,000BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. VanEck Vectors Generic Drugs ETF ExpensesTypeGNRXHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.50%0.56%0.54%0.48%0.51%Other Expenses2.44%0.40%0.54%0.34%0.58%Total Expense2.94%0.72%0.70%0.58%0.70%Fee Waiver-2.37%-0.53%-0.55%-0.22%-0.56%Net Expense0.57%0.60%0.60%0.54%0.58% VanEck Vectors Generic Drugs ETF (GNRX) ExposureGNRX Sector ExposureGNRX Industry ExposureFull Holdings Details Similar ETFsProShares UltraShort Nasdaq BiotechnologyNASDAQ:BISJPMorgan Healthcare Leaders ETFNASDAQ:JDOCHorizon Kinetics Medical ETFNASDAQ:MEDXFirst Trust Nasdaq Pharmaceuticals ETFNASDAQ:FTXHInvesco Nasdaq Biotechnology ETFNASDAQ:IBBQ GNRX ETF - Frequently Asked Questions What does GNRX invest in? VanEck Vectors Generic Drugs ETF is a equity fund issued by Van Eck. GNRX focuses on health care investments and follows the Indxx Global Generics & New Pharma Index. The fund's investments total to approximately $3.36 million assets under management. What is the management fee for VanEck Vectors Generic Drugs ETF? VanEck Vectors Generic Drugs ETF's management fee is 0.50% and has other expenses of 2.44%. However, GNRX has a fee waiver of -2.37% to reimburse the expenses. The net expense ratio for GNRX is 0.57%. What other stocks do shareholders of VanEck Vectors Generic Drugs ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Vectors Generic Drugs ETF investors own include Bausch Health Companies (BHC), Saul Centers (BFS), Virtus LifeSci Biotech Products ETF (BBP), Bellevue Healthcare (BBH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ArrowMark Financial (BANX), Yamana Gold (AUY), A. O. Smith (AOS), Sphere 3D (ANY) and Andersons (ANDE). This page (NASDAQ:GNRX) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchDems have chosen Biden replacement?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsProtect Your Bank Account Before It’s Too LateWeiss RatingsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA ‘DeFi Summer’ Projected!Crypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Vectors Generic Drugs ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
